We’re delighted to report that 2025 was an outstanding year for Cumberland!
We delivered a strong financial performance, expanded our global reach, advanced our clinical programs and added to our commercial portfolio — all while remaining focused on our mission of delivering unique products that improve the quality of patient care.
We reported strong financial results in the fourth quarter and for the full year:
- Fourth quarter revenue totaled $13.7 million, up 31% over the prior year period.
- Full-year revenue reached $44.5 million, with $4.9 million in cash flow from operations.
- We also delivered a profitability turnaround, improving adjusted earnings by $2.7 million, while strengthening our balance sheet and reducing debt more than $10 million.
We continued to expand Cumberland’s international presence, with several key milestones:
- Vibativ® received approval in China, the world’s second-largest pharmaceutical market.
- Vibativ launched in Saudi Arabia, with initial product sales and patient treatments.
- Our ibuprofen injection product was approved for sale in Mexico.
During the year, we expanded our commercial portfolio with the addition of Talicia®, a leading treatment for H. pylori infections, strengthening our presence in gastrointestinal care.
We also reached an important reimbursement milestone when the Centers for Medicare & Medicaid Services issued a permanent J-Code for Caldolor®, enhancing product access and simplifying hospital billing.
Our development pipeline advanced with the release of breakthrough clinical data from our Duchenne muscular dystrophy program, which has now received Orphan Drug, Rare Pediatric Disease and Fast Track Designations from the FDA.
As we enter 2026, Cumberland is well positioned with a stronger financial foundation, an expanding global footprint, a growing portfolio and a promising pipeline.
We look forward to building on this momentum!